Luke Miels sheds light on GSK internal changes, ‘very busy’ BD scene
GSK has been reworking its R&D process, complete with a recent revamp on the research side. And according to chief commercial officer Luke Miels, the overhaul has had an impact on his team, too.
The entire organization has changed “a lot” over the past few years, Miels said at a fireside chat during the Redburn Atlantic CEO Conference. The key idea? To make sure that people on the commercial side who are working with the R&D team on projects are both “scientifically fluent” and “commercially credible” — and vice versa within the R&D unit. Under a “very flat structure,” therapeutic leadership teams are chaired by a commercial person, with the R&D leader being a key partner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
